The company's most advanced candidate, setrusumab for osteogenesis imperfecta (OI), is approaching critical milestones. Two pivotal Phase 3 trials for setrusumab are fully enrolled, with interim ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung ...

Mereo is also active in rare disease R&D and intends to complete a strategic partnership for setrusumab for the treatment of osteogenesis imperfecta before beginning a pivotal phase 3 study ...

Ultragenyx's pipeline is rich with potential, spanning multiple rare genetic disorders. The company's most advanced candidate, setrusumab for osteogenesis imperfecta (OI), is approaching critical ...